Conclusion: These results reveal that Re-188(I)-trastuzumab could be an appropriate radioimmunotherapeutic agent for the treatment of HER2/neu-overexpressing cancers. (C) 2009 Elsevier Inc. All rights reserved.”
“Aim: Trastuzumab is a monoclonal antibody that is used in treating breast cancer. We labeled this monoclonal antibody with lutetium-177 and performed in vitro quality control tests as a first step in the production of a new radiopharmaceutical.

Material and Methods: Trastuzumab was labeled with lutetium-177 using DOTA as chelator. Radiochemical purity and stability in buffer and

human blood serum were determined using thin layer chromatography. Immunoreactivity and toxicity of the complex were tested on MCF7 breast cancer cell line.

Results: The radiochemical purity of the complex was 96 +/- 0.9%. The stabilities in phosphate buffer and in human learn more blood serum at 96 h postpreparation were 93 +/- 1.2% and 85 +/- 3.5%, respectively. The immunoreactivity of the complex was 89 +/- 1.4%. At a concentration of 1 nM, the complex killed 70 +/- 3% of MCF7 cells. At 1.9

nM, 90 +/- 5% of the cells were killed.

Conclusions: The results showed that the new Complex Could be considered for further evaluation in animals and possibly in humans as a new radiopharmaceutical for use in radioimmunotherapy find more against breast cancer. (C) 2009 Elsevier Inc. All rights reserved.”
“c-Met is a receptor tyrosine kinase involved in tumor cell growth, invasion, metastases and angiogenesis. Overexpression Microtubule Associated of c-Met is frequently observed in several tumor types. Here, we report the in vitro cell-binding properties and biodistribution and SPECT/CT imaging in glioma (U87MG) xenograft-bearing mice of (125)I-labeled c-Met-binding peptides (cMBPs) including analogs conjugated to amino acid

and aliphatic carbon linkers. In vitro assays showed that the peptide without any linker and those with GGG and 8-aminooctanoic acid linkers had low cellular internalization and that IC(50) values of peptides were 1.5 mu M, 65 nM and 85.3 nM, respectively. Biodistribution studies showed the GGG-containing peptide had higher tumor uptake and a higher tumor-to-blood activity concentration ratio than other receptor-binding ligands. SPECT/CT studies with a dedicated small-animal imaging system were performed in U87MG-bearing athymic mice. Although U87MG tumor xenografts could be visualized by SPECT/micro-CT using the various 1251 labeled cMBPs, image contrast and overall quality were unremarkable. (C) 2009 Elsevier Inc. All rights reserved.”
“Introduction: Malignant mesothelioma is a highly aggressive tumor originating in the pleura, peritoneum and pericardium, and the prognosis of patients undergoing current treatment remains poor. To develop new therapies, it is important to have a noninvasive imaging system for evaluating the efficacy of such prospective treatments.